Lundbeck races ahead in French antidepressant market  

2009.08.18
Following restructuring of its sales operation, Danish pharmaceutical company Lundbeck has gained significant market share in France over the last three years
Following restructuring of its sales operation, Danish pharmaceutical company Lundbeck has gained significant market share in France over the last three years, writes financial daily newspaper Børsen.
 
Since 2006, Lundbeck's antidepressant Cipralex has more than doubled its market share in France, where it is sold under the name Seroplex. Lundbeck now has 20.5% of the antidepressants market measured by value. This puts Lundbeck ahead of Wyeth & Pfizer (Efexor), and GlaxoSmithKline (Paxil), which have 14.2% and 13.3% market share respectively.
 
A Lundbeck spokesperson told Børsen that France is one of Lundbeck's most important markets, and that the company was very satisfied with the speed with which it is gaining market share. The sales restructuring exercise has been aimed at increasing the number of GP visits made by its 600-strong sales force, while also bringing back office functions closer to the market.
 
According to Børsen, the French market for the treatment of central nervous system (CNS) diseases is worth the equivalent of DKK 30bn (USD 5.7bn), making it the fourth largest in the world and second largest in Europe after Germany.
 
Link > Lundbeck                   

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×